Treatment of sexually transmitted infections for HIV prevention: End of the road or new beginning?

AIDS

Volumn 24, Issue SUPPL. 4, 2010, Pages

  Hayes, Richard ^a   Watson Jones, Deborah ^b   Celum, Connie ^c   Van De Wijgert, Janneke ^d,e   Wasserheit, Judith ^c,f  

^a MRC Tropical Epidemiology Group   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF WASHINGTON   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^f Fred Hutchinson Cancer Research Center   (United States)

Author keywords

bacterial vaginosis; HIV; prevention and control; randomized controlled trials; sexually transmitted diseases; sub Saharan Africa

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; HEALTH CARE POLICY; HEALTH PROGRAM; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION CONTROL; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; VAGINITIS; WART VIRUS;

DISEASE OUTBREAKS; FEMALE; HIV INFECTIONS; HUMANS; MALE; POLICY; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEXUALLY TRANSMITTED DISEASES;

EID: 78349239613     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/01.aids.0000390704.35642.47     Document Type: Review

References (63)

1. Gray RH, Wawer MJ. Reassessing the hypothesis on STI control for HIV prevention. Lancet 2008; 371:2064-2065.
2. Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19:61-77.
3. Cohen MS, Pilcher CD. Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis 2005; 191:1391-1393.
4. Kaul R, Nagelkerke NJ, Kimani J, Ngugi E, Bwayo JJ, Macdonald KS, et al. Prevalent herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to multiple sexually transmitted infections. J Infect Dis 2007; 196:1692-1697.
5. Sexton J, Garnett G, Rottingen J-A. Metaanalysis and metare-gression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection. Sex Transm Dis 2005; 32:351-357.
6. Hayes RJ, Schulz KF, Plummer FA. The cofactor effect of genital ulcers on the per-exposure risk of HIV transmission in sub-Saharan Africa. J Trop Med Hyg 1995; 98:1-8.
7. Glynn JR, Biraro S, Weiss HA. Herpes simplex virus type 2: a key role in HIV incidence. AIDS 2009; 23:1595-1598.
8. Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis 2008; 35:946-959.
9. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342:921-929.
10. Barnabas R, Weiss HA, Wasserheit JN. Role of co-infections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis of malaria, HSV-2 and TB co-infections. ISSTDR Conference; London; 2009; abstract OS3.3.03.
11. Cohen MS, Hoffman IF, Royce RA, Kazembe P, Dyer JR, Daly CC, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 1997; 349:1868-1873.
12. Price MA, Zimba D, Hoffman IF, Kaydos-Daniels SC, Miller WC, Martinson F, et al. Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial. Sex Transm Dis 2003; 30:516-522.
13. McClelland RS, Wang CC, Mandaliya K, Overbaugh J, Reiner MT, Panteleeff DD, et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001; 15:105-110.
14. Wang CC, McClelland RS, Reilly M, Overbaugh J, Emery SR, Mandaliya K, et al. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 2001; 183:1017-1022.
15. Myer L, Kuhn L, Stein ZA, Wright TC, Denny L. Intravaginal practices, bacterial vaginosis, and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis 2005; 5:786-794.
16. Taha TE, Hoover DR, Dallabetta GA, Kumwenda NI, Mtimavalye LA, Yang LP, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 1998; 12:1699-1706.
17. Martin HL, Richardson BA, Nyange PM, Lavreys L, Hillier SL, Chohan B, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999; 180:1863-1868.
18. Myer L, Denny L, Telerant R, Souza M, Wright TC Jr, Kuhn L. Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J Infect Dis 2005; 192:1372-1380.
19. Van De Wijgert JHHM, Morrison CS, Cornelisse PGA, Munjoma M, Moncada J, Awio P, et al. Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-1 acquisition in African women. J Acquir Immune Defic Syndr 2008; 48:203-210.
20. Laga M, Manoka A, Kivuvu M, Malele B, Tuliza M, Nzila N, et al. Nonulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993; 7:95-102.
21. Kapiga SH, Lyamuya EF, Lwihula GK, Hunter DJ. The incidence of HIV infection among women using family planning methods in Dar Es Salaam, Tanzania. AIDS 1998; 12:75-84.
22. Hester RA, Kennedy SB. Candida infection as a risk factor for HIV transmission. J Women's Health 2003; 5:487-494.
23. van de Wijgert J, Morrison C, Brown J, Kwok C, Van Der Pol B, Chipato T, et al. Disentangling the contributions of reproductive tract infections on HIV acquisition in African women. Sex Transm Dis 2009; 36:357-364.
24. Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346:530-536.
25. Mayaud P, Mosha F, Todd J, Balira R, Mgara J, West B, et al. Improved treatment services significantly reduce the prevalence of sexually transmitted diseases in rural Tanzania: results of a randomized controlled trial. AIDS 1997; 11:1873-1880.
26. Wawer MJ, Sewankambo NK, Serwadda D, Quinn TC, Paxton LA, Kiwanuka N, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Lancet 1999; 353:525-535.
27. Kamali A, Quigley M, Nakiyingi J, Kinsman J, Kengeya-Kayondo J, Gopal R, et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet 2003; 361:645-652.
28. GregsonS,AdamsonS,PapayaS,MundondoJ,Nyamukapa CA, Mason PR, et al. Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in Eastern Zimbabwe. PLoS Med 2007; 4:e102.
29. White RG, Orroth KK, Glynn JR, Freeman EE, Bakker R, Habbema J, et al. Treating curable sexually transmitted infections to prevent HIV in Africa. Still an effective control strategy? J Acquir Immune Defic Syndr 2008; 47:346-353.
30. Buvé A, ChangaluchaJ, Mayaud P, Gavyole A, MugeyeK, Todd J, et al. How many patients with a sexually transmitted infection are cured by health services? A study from Mwanza region, Tanzania. Trop Med Int Health 2001; 6:971-979.
31. Orroth KK, Korenromp EL, White RG, Changalucha J, de Vlas SJ, Gray RH,et al. Comparisonof STD prevalencesin the Mwanza, Rakai and Masaka trial populations: the role of selection bias and diagnostic errors. Sex Transm Infect 2003; 79:98-105.
32. Korenromp EL, White RG, Orroth KK, Bakker R, Kamali A, Serwadda D, et al. Determinants of the impact of sexually transmitted infection treatment on prevention of HIV infection: a synthesis of evidence from the Mwanza, Rakai, and Masaka intervention trials. Journal of Infectious Diseases 2005; 191 (Suppl 1):S168-S175.
33. Ghys PD, Diallo MO, Ettiègne-Traoré V, Satten GA, Anoma CK, Maurice C, et al. Effect of interventions to control sexually transmitted disease on the incidence of HIV infection in female sex workers. AIDS 2001; 15:1421-1431.
34. Laga M, Alary M, Nzila N, Manoka AT, Tuliza M, Behets F, et al. Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet 1994; 344:246-248.
35. Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, Keli F, et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers. JAMA 2004; 291:2555-2562.
36. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Bais-ley K, Mugeye K, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560-1571.
37. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Mor-etlwe S, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109-2119.
38. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185:45-52.
39. del Mar Pujades Rodríguez M, ObasiA, Mosha F, ToddJ, Brown D, Changalucha J, et al Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. AIDS 2002 16 451-462.
40. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35:435-445.
41. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83.
42. Kapiga SH, Sam NE, Bang H, Ni Q, Ao TT, Kiwelu I, et al. The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. J Infect Dis 2007; 195:1260-1269.
43. Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, Jaoko W, et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS 2007; 21:589-598.
44. Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009; 15:886-892.
45. NagotN,OuedraogoA,FoulongneV,Konaté I,WeissHA,Vergne L, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356:790-799.
46. Dunne EF, Whitehead S, Sternberg M, Thepamnuay S, Leelawiwat W, McNicholl J, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008; 49:77-83.
47. Zuckerman RA, Lucchetti A, Whittington WL, Sánchez J, Coombs RW, Magaret A, et al. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. AIDS 2009; 23:479-483.
48. Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/ HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008; 198:1804-1808.
49. Cowan FM, Pascoe SJ, Barlow KL, Langhaug LF, Jaffar S, Hargrove JW, et al. A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers. Sex Transm Infect 2008; 84:548-553.
50. Delany S, Mlaba N, Clayton T, Akpomiemie G, Capovilla A, Legoff J, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009; 23:461-469.
51. Tanton C, Weiss HA, Rusizoka M, LeGoff J, Changalucha J, Baisley K, et al. Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial. J Infect Dis 2010; 201:1285-1297.
52. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427-439.
53. Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, et al. Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010; 375:824-833.
54. White RG, Orroth KK, Korenromp EL, Bakker R, Wambura M, Sewankambo NK, et al. Can population differences explain the contrasting results of the Mwanza, Rakai, and Masaka HIV/ sexually transmitted disease intervention trials? A modeling study. J Acquir Immune Defic Syndr 2004; 37:1500-1513.
55. Johnson LF, Coetzee DJ, Dorrington RE. Sentinel surveillance of sexually transmitted infections in South Africa: a review. Sex Transm Infect 2005; 81:287-293.
56. Wasserheit JN, Aral SO. The dynamic topology of sexually transmitted disease epidemics: implications for prevention strategies. J Infect Dis 1996; 174 (Suppl 2):S201-S213.
57. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 2005; 353:1899-1911.
58. Austin MN, Beigi RH, Meyn LA, Hillier SL. Microbiologic response to treatment of bacterial vaginosis with topical clin-damycin or metronidazole. J Clin Microbiol 2005; 43:4492-4497.
59. Pitsouni E, Iavazzo C, Falagas ME. Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvo-vaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials. Am J Obstetr Gynecol 2008; 198:153-160.
60. Taha TE, Kumwenda NI, Kafulafula G, Makanani B, Nkhoma C, Chen S, et al. Intermittent intravaginal antibiotic treatment of bacterial vaginosis in HIV-uninfected and -infected women: a randomized clinical trial. PLoS Clin Trial. 2007; 2:e10.
61. McClelland RS, Richardson BA, Hassan WM, Chohan V, Lavreys L, Mandaliya K, et al. Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis 2008; 197:1361-1388.
62. Abad CL, Safdar N. The role of lactobacillus probiotics in the treatment or prevention of urogenital infections: a systematic review. J Chemother 2009; 21:243-252.
63. Auvert B, Lissouba P, Cutler E, Zarca K, Puren A, Taljaard D. Association of oncogenic and nononcogenic human papillo-mavirus with HIV incidence. J Acquir Immune Defic Syndr 2010; 53:111-116.